AR089553A1 - Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal - Google Patents
Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasalInfo
- Publication number
- AR089553A1 AR089553A1 ARP120101721A ARP120101721A AR089553A1 AR 089553 A1 AR089553 A1 AR 089553A1 AR P120101721 A ARP120101721 A AR P120101721A AR P120101721 A ARP120101721 A AR P120101721A AR 089553 A1 AR089553 A1 AR 089553A1
- Authority
- AR
- Argentina
- Prior art keywords
- oil
- testosterone
- testosterone gel
- intranasal
- lipophilic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Abstract
También se refiere a métodos y a sistemas de aplicadores sin aire, de múltiples dosis, prellenados para la administración pernasal del gel de testosterona nasal. Reivindicación 1: Un gel de testosterona intranasal para la administración tópica en una cavidad nasal para controlar la liberación de testosterona durante un período de por lo menos aprox. 6 horas después de la administración en la cavidad nasal para proveer un reemplazo de testosterona en un hombre para el tratamiento de la deficiencia de testosterona en el hombre, sin causar un pico repentino inaceptable en el nivel sanguíneo de testosterona en el hombre durante la vida útil de la dosis, dicho gel de testosterona intranasal comprende: (a) testosterona en una cantidad efectiva para tratar la deficiencia de testosterona en el hombre; (b) por lo menos un vehículo lipófilo o parcialmente lipófilo; (c) un supersolvente para aumentar la solubilidad de testosterona en dicho gel de testosterona intranasal; y (d) un agente regulador de la viscosidad en una cantidad efectiva para controlar la liberación de dicha testosterona de dicho gel de testosterona intranasal, en donde dicho gel de testosterona intranasal no necesita un tensioactivo. Reivindicación 5: El gel de testosterona intranasal de acuerdo con la reivindicación 4, en donde dicho aceite es seleccionado entre un grupo de aceites que consiste en aceite de ricino, aceite de almendras, aceite de linaza, aceite de canola, aceite de coco, aceite de maíz, aceite de semilla de algodón, aceite de palma, aceite de maní, aceite de semilla de amapola, aceite de soja y mezclas de estos. Reivindicación 13: El gel de testosterona intranasal de acuerdo con la reivindicación 1, en donde dicho vehículo lipófilo es seleccionado entre un grupo de vehículos lipófilos que consiste en una aceite mineral, una parafina, un isopropil miristato, un isopropil palmitato, un capril caprilato, un metil estearato, un triglicérido de cadena mediana, un propilenglicol, un dicaprilocaprato, un alcohol cetoestearílico, un alcohol estearílico y mezclas de estos. Reivindicación 18: El gel de testosterona intranasal de acuerdo con una cualquiera de las reivindicaciones 1 a 13, en donde dicho supersolvente es seleccionado entre un grupo que consiste en dimetil isosorbida, dietilenglicol monoetil éter, glicerol, polietilenglicol, 1-metil 2-pirrolidona y mezclas de estos. Reivindicación 24: El gel de testosterona intranasal de acuerdo con la reivindicación 23, en donde dicho agente espesante o gelificante es seleccionado entre un grupo de agentes espesantes o gelificantes que consiste en una celulosa, un derivado de celulosa, una hidroxipropil celulosa, una hidroxietil celulosa, una goma lipófila, un polímero acrílico, carbopol, un polisacárido, un carbómero, alcohol polivinílico, povidona, un dióxido de silicio, un alcohol cetílico, un ácido esteárico, una cera, una cera de abejas, un petrolato, un triglicérido, lanolina, gliceril behenato, inulina o una mezcla de estos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486324P | 2011-05-15 | 2011-05-15 | |
| US201161486634P | 2011-05-16 | 2011-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089553A1 true AR089553A1 (es) | 2014-09-03 |
Family
ID=46579248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101720A AR086409A1 (es) | 2011-05-15 | 2012-05-16 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino |
| ARP120101721A AR089553A1 (es) | 2011-05-15 | 2012-05-16 | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101720A AR086409A1 (es) | 2011-05-15 | 2012-05-16 | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino |
Country Status (16)
| Country | Link |
|---|---|
| EP (3) | EP2714006B1 (es) |
| JP (9) | JP2014513716A (es) |
| KR (9) | KR102088038B1 (es) |
| CN (4) | CN110613679A (es) |
| AR (2) | AR086409A1 (es) |
| AU (10) | AU2012257490A1 (es) |
| BR (2) | BR112013029332A2 (es) |
| CA (3) | CA2836405C (es) |
| DK (1) | DK2714006T3 (es) |
| EA (1) | EA201391701A1 (es) |
| ES (1) | ES2859784T3 (es) |
| IL (2) | IL229401A0 (es) |
| MX (4) | MX2020008599A (es) |
| PL (1) | PL2714006T3 (es) |
| WO (2) | WO2012156822A1 (es) |
| ZA (2) | ZA201309264B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| KR102088038B1 (ko) * | 2011-05-15 | 2020-03-13 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템 |
| US8971800B2 (en) * | 2011-05-31 | 2015-03-03 | Qualcomm Incorporated | Methods and apparatus for improving NFC activation and data exchange reporting mechanisms |
| HUE055562T2 (hu) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| WO2014093818A2 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| EP3653213B1 (en) * | 2013-10-07 | 2024-02-21 | Antares Pharma, Inc. | Hematocrit modulation through needle assisted jet injection of testosterone |
| WO2015127012A1 (en) | 2014-02-19 | 2015-08-27 | Wotton Paul K | Needle assisted jet injection administration of testosterone compositions |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
| WO2016123317A1 (en) * | 2015-01-28 | 2016-08-04 | Prometheon Pharma, Llc | Topical formulations of growth factors |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
| IL300437A (en) | 2016-01-07 | 2023-04-01 | Viramal Ltd | Gel preparations for administering a drug through the skin to maximize drug concentrations in the rough layer and serum and methods of using them |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| CN109069750B (zh) | 2016-04-25 | 2021-09-07 | 科斯卡家族有限公司 | 药物输送系统 |
| BR112018075073A2 (pt) * | 2016-06-02 | 2019-04-30 | Acerus Pharmaceutical Corporation | composições nasais de canabidiol |
| SG11201810628XA (en) | 2016-06-03 | 2018-12-28 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| RU2019123307A (ru) | 2017-01-20 | 2021-02-20 | М Эт П Фарма Аг | Фармацевтические композиции для назального введения для снижения рисков воздействия загрязнителей воздуха |
| EP3641424B1 (en) | 2017-06-17 | 2022-05-04 | LG Electronics Inc. | Method for registering a user equipment with a network slice in a wireless communication system and user equipment therefor |
| EP3718550A4 (en) * | 2017-11-27 | 2021-08-25 | ASKA Pharmaceutical Co., Ltd. | POWDER PREPARATION FOR NASAL ADMINISTRATION |
| CN112020361A (zh) * | 2018-02-02 | 2020-12-01 | 阿克罗斯生物制药公司 | 睾酮治疗方法 |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| CN108771622B (zh) * | 2018-07-11 | 2022-01-07 | 尹振图 | 一种自闭式针形滴嘴及眼药水瓶 |
| CN113164384A (zh) | 2018-10-26 | 2021-07-23 | 维拉莫有限公司 | 黏膜粘附性凝胶组合物 |
| EP3659583B1 (en) | 2018-11-30 | 2023-06-07 | Viramal Limited | A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
| EA202191378A1 (ru) * | 2018-12-14 | 2021-10-04 | Ацерус Биофарма Инк. | Активные сложноэфирные производные тестостерона, их композиции и применения |
| JP7508035B2 (ja) | 2020-03-10 | 2024-07-01 | オムロン株式会社 | 電子機器及び近接センサ |
| CN112121049B (zh) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用 |
| KR20230107307A (ko) * | 2020-11-19 | 2023-07-14 | 아코우지아 테라포이틱스 게엠베하 | 비수성 겔 조성물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| DE4214953C2 (de) | 1992-05-06 | 1995-05-18 | Arrowdean Ltd | Arzneimittel zur Erhöhung des Testosteronspiegels |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5576071A (en) | 1994-11-08 | 1996-11-19 | Micron Technology, Inc. | Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds |
| JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
| DK1510213T3 (da) * | 1997-11-10 | 2009-03-23 | Strakan Int Ltd | Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| CA2463384A1 (en) * | 2001-10-12 | 2003-04-17 | Cns, Incorporated | Hydrating nasal gel and applicator |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| JP5619337B2 (ja) * | 2003-10-10 | 2014-11-05 | フェリング ビー．ブイ． | 皮膚残渣を最小限に抑えるための経皮的医薬製剤 |
| EP1530965B1 (en) | 2003-11-11 | 2006-03-08 | Mattern, Udo | Controlled release delivery system of sexual hormones for nasal application |
| EP1827498A2 (de) * | 2004-12-09 | 2007-09-05 | Bayer HealthCare AG | Stabilisierung von glucocorticoidestern mit säuren |
| JP5401092B2 (ja) * | 2005-06-03 | 2014-01-29 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 経皮的薬物送達のための方法および組成物 |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| CN101099742A (zh) * | 2006-07-06 | 2008-01-09 | 上海富海科申药业有限公司 | 能够减少皮肤刺激的睾酮凝胶制剂 |
| PT2068825E (pt) | 2006-10-04 | 2011-02-11 | M & P Patent Ag | Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores |
| BRPI0809124A8 (pt) * | 2007-03-23 | 2015-11-24 | Unimed Pharmaceuticals Llc | Composições e métodos para tratamento de hipogonadismo pediátrico |
| CN101801388B (zh) * | 2007-09-20 | 2012-07-04 | 株式会社资生堂 | 透皮吸收制剂 |
| PL2500062T3 (pl) * | 2007-11-13 | 2015-12-31 | Curadis Gmbh | Steroidy C-19 do określonych zastosowań terapeutycznych |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| KR102088038B1 (ko) * | 2011-05-15 | 2020-03-13 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템 |
-
2012
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active IP Right Grant
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko active Application Filing
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Application Discontinuation
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/en active Application Filing
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko active Application Filing
- 2012-05-15 MX MX2020008599A patent/MX2020008599A/es unknown
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Application Discontinuation
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/en active Active
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko active Application Filing
- 2012-05-15 CA CA2836405A patent/CA2836405C/en active Active
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Application Discontinuation
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/en active Application Filing
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active IP Right Grant
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh active Active
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Application Discontinuation
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/en active Active
- 2012-05-15 CA CA3034552A patent/CA3034552C/en active Active
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 PL PL12748245T patent/PL2714006T3/pl unknown
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 CA CA2836398A patent/CA2836398C/en active Active
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/en not_active Withdrawn
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
-
2013
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-11-15 MX MX2019003340A patent/MX2019003340A/es active IP Right Grant
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
-
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
-
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
-
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089553A1 (es) | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal | |
| CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| UY32582A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
| AR070083A1 (es) | Composiciones y metodos para tratar enfermedades de la una | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2015016277A (es) | Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa. | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| MX348705B (es) | Composiciones farmacéuticas y métodos de administración relacionados. | |
| AR078846A1 (es) | Composicion para el tratamiento de la enfermedad de alzheimer | |
| PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| JP2014510042A5 (es) | ||
| NI201400122A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| PE20130657A1 (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
| CL2017001913A1 (es) | Composición tópica curativa | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |